Efficacy News and Research

RSS
Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Oxygen Biotherapeutics announces CRADA Agreement amendment

Oxygen Biotherapeutics announces CRADA Agreement amendment

Researchers discover HIV-1 resists AZT drug

Researchers discover HIV-1 resists AZT drug

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

FDA grants Optovue  510(k) clearance on Normative Database for RTVue OCT device

FDA grants Optovue 510(k) clearance on Normative Database for RTVue OCT device

Emergent BioSolutions signs contract with HHS to develop rPA anthrax vaccine

Emergent BioSolutions signs contract with HHS to develop rPA anthrax vaccine

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

SBi reports continuing growth for S.T.A.R. ankle arthroplasty implant system

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

BCM-95 curcumin exhibits anti-inflammatory properties

BCM-95 curcumin exhibits anti-inflammatory properties

Diclectin's effectiveness for morning sickness: Report

Diclectin's effectiveness for morning sickness: Report

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Abbott to present two drug eluting stents data at TCT symposium

Abbott to present two drug eluting stents data at TCT symposium

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

Researchers develop infected tissue model for Aganocide compounds

Researchers develop infected tissue model for Aganocide compounds

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.